Search results
PROCEED evaluated the safety and survival profile of PROVENGE. Among patients in the lowest baseline prostate-specific antigen (PSA) quartile (≤5.27 ng/mL), nearly half (44.1%) of the men in the registry received no additional cancer treatments for at least 1 year.
20 paź 2020 · Specifically, overall survival was 35.2 months with any-line Provenge versus 20.7 months without the immunotherapy. These findings highlight that including Provenge at any point during treatment prolongs the life of men with mCRPC by more than one year and reduces their risk of death by more than 40%.
14 paź 2020 · Men who received PROVENGE as a first-line treatment had a 44% reduction in the risk of death at three years compared to those receiving oral agents as first-line treatment (adjusted hazard ratio,...
9 wrz 2019 · Treatment with the immunotherapy Provenge ( sipuleucel-T) in a real-world setting is showing similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in clinical trials, a study shows.
17 lut 2020 · In the comparison of use at any time, those who ever used Provenge had a median overall survival of 35.2 months, compared with 20.7 months for those who never used the vaccine. This survival advantage of 14.5 months translates to a 45% lower risk of death.
18 maj 2019 · In this study the estimated improvement in median survival varied from 13.0 months in the lowest baseline PSA quartile to 2.8 months in the highest PSA quartile, the men with the lowest baseline PSA did much better and survived longer.
13 lut 2020 · New study of 6,000+ Medicare patients with advanced prostate cancer shows adding PROVENGE (sipuleucel-T) to treatment reduced risk of death by 45%.
